InflaRx (IFRX) to Release Earnings on Friday

InflaRx (NASDAQ:IFRX) will be posting its quarterly earnings results before the market opens on Friday, November 8th. Analysts expect InflaRx to post earnings of ($0.27) per share for the quarter.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). InflaRx had a negative return on equity of 47.03% and a negative net margin of 44,046.09%. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.04 million. On average, analysts expect InflaRx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

InflaRx Stock Performance

Shares of NASDAQ IFRX opened at $1.53 on Thursday. The company has a 50 day simple moving average of $1.53 and a two-hundred day simple moving average of $1.51. The company has a market capitalization of $90.09 million, a price-to-earnings ratio of -1.72 and a beta of 1.57. InflaRx has a fifty-two week low of $1.14 and a fifty-two week high of $2.10.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of InflaRx in a research note on Wednesday, September 25th.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.